did fda ban compounded semaglutide 🚨 Moves to Permanently Shut Down GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like and tirzepatide, signaling a major shift in how these FDA says 'no clinical need'

Although these data show a favorable riskbenefit profile for GLP-1RA, there are differences between individual drugs with respect to their effect on cardiorenal outcomes in the separate trials

PMID: 37276988

These prescription drugs mimic the effects of hormones in the body that regulate blood sugar levels and appetite

In hindsight, many industry experts have argued that building a scalable business model on a transient regulatory condition is like constructing a house on sand

On average, over 80% of participants experienced significant weight reduction, with some studies showing participants losing up to 20% of their body weight over the course of treatment.